|Systematic IUPAC name
3D model (JSmol)
|Molar mass||347.28 g·mol−1|
|P01AR01 (WHO) QP51AD01 (WHO)|
|89 % Hepatic|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Arsthinol (INN) is an antiprotozoal agent. It was synthesized for the first time in 1949 by Ernst A.H. Friedheim by complexation of acetarsol with 2,3-dimercaptopropanol (British anti-Lewisite) and has been demonstrated to be effective against amoebiasis and yaws. It was marketed few years later by Endo Products (Balarsen, Tablets, 0.1 g). Among trivalent organoarsenicals, arthinol was considered as very well tolerated. Recently, it was studied for its anticancer activity.
- Cristau, B; Chabas, ME; Placidi, M (1975). "Voies et cinétiques d'excrétion de l'arsenic chez le Cobaye après injection de divers médicaments organo-arséniés". Ann Pharm Fr. 33: 577–89.
- Friedheim, Ernst AH (1949). "A Five Day Peroral Treatment of Yaws with STB, a New Trivalent Arsenical". Am J Trop Med Hyg. s1-29 (2): 185–188.
- Anonyme (1953). "New and nonofficial remedies; arsthinol". J Am Med Assoc. 152: 531.
- Brown, CH; Gebhart, WF; Reich, A (1956). "Intestinal amebiasis: incidence, symptoms, and treatment with arsthinol (Balarsen)". JAMA. 160: 360–363. doi:10.1001/jama.1956.02960400018005.
- Gibaud, S; Alfonsi, R; Mutzenhardt, P; et al. (2006). "(2-Phenyl-[1, 3, 2] dithiarsolan-4-yl)-methanol derivatives show in vitro antileukemic activity". J Organomet Chem. 691: 1081–1084. doi:10.1016/j.jorganchem.2005.11.007.
- Becherirat, S.; Lanhers, M.-C.; Socha, M.; Yemloul, M.; Astier, A.; Loboda, C.; Aniceto, N.; Gibaud, S. (2013). "The antitumor effects of an arsthinol-cyclodextrin complex in an heterotopic mouse model of glioma". Eur J Pharm Biopharm. 85: 560–568. doi:10.1016/j.ejpb.2013.06.021.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|